Modality
Bispecific Ab
MOA
TNFi
Target
PARP
Pathway
JAK/STAT
Urothelial CaIPF
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Feb 2030
Phase 1Current
NCT05299257
1,356 pts·IPF
2021-05→2030-02·Terminated
NCT06595224
1,968 pts·IPF
2024-03→TBD·Not yet recruiting
3,324 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-203.9y awayPh2 Data· IPF
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2030-02-20 · 3.9y away
IPF
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05299257 | Phase 1/2 | IPF | Terminated | 1356 | DAS28 |
| NCT06595224 | Phase 1/2 | IPF | Not yet recr... | 1968 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP |